Pharmacokinetics of ertapenem in healthy young volunteers. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of ertapenem in healthy young volunteers.

Pharmacokinetics of ertapenem in healthy young volunteers.

http://www.wikidata.org/entity/Q34141850

about

Carbapenems The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay.Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.Ertapenem: review of a new carbapenem.Tigecycline: a novel glycylcycline antibiotic.Intra-abdominal infections: considerations for the use of the carbapenems.Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.Carbapenems in the USA: focus on doripenem.Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.Pharmacokinetics of ertapenem in colorectal tissue.A Critical Review of Analytical Methods for Determination of Ertapenem Sodium.Is there a role for microsampling in antibiotic pharmacokinetic studies?β-Lactams and β-Lactamase Inhibitors: An Overview.Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Design, synthesis, and evaluation of prodrugs of ertapenem.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery.Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method.Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.Population pharmacokinetics of ertapenem in juvenile and old rats.Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews.The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.Unbound fraction of ertapenem in intensive care unit patients.

P2860

Q28286055-96DD9115-CFC4-4B55-8197-7452B89C2A53 Q28289744-252A4957-2E6A-4B16-90F2-0472CEA04589 Q30837114-652076D6-D819-47E6-9D86-92B40EFB62C4 Q34026343-B67BA067-C20F-4CA6-AE45-16B0453856D0 Q34188814-CEB8BB06-C07A-46D0-8C17-B4A7867EE495 Q34244192-871B5455-7679-4B80-95AE-BFCA76AF4E31 Q34348830-0F435F7E-5E81-4B83-9FB3-BA25BE36F8C7 Q35065899-5DC0DAA9-B065-48C8-8491-CD71746578AA Q35385108-4730F855-CB3A-43CF-8FE8-CC966E120621 Q35547612-6BD07640-BF59-40D6-B01E-6FA7AE23729F Q35617587-D9154EC6-6733-4A32-A07B-FC6CC013A764 Q36018937-BF16EB32-E50B-4F75-8C16-C1E076D6EA81 Q36066200-3FFBBCD3-A73B-4AEF-9159-7DA1E2E84F03 Q36379330-DADFB4FC-2618-4C44-9274-49D5599732D0 Q36719679-08D87D81-C4B6-4A04-A0BD-8A25C4C9D9BA Q36719706-672463EF-ACA8-4547-A7C7-922BB901BB03 Q36960048-34ADF018-3A45-4EBE-8843-EECA62C582A0 Q37412959-A6B74987-FF3D-4E4B-8743-0581C98FED52 Q37568571-820BCD5D-6422-4261-87D0-F65963283614 Q37643628-216E8F81-655B-413B-B4B2-0FAD0DA88B57 Q38244221-DB1AD11E-FFC5-4265-B473-9C961A7348B5 Q38479091-E0005C2B-4AE2-4D99-BF1B-0BA6649168FE Q38726679-F4124739-19BF-4970-AFAA-4568F6088E4C Q38810590-4BA7E67C-CDE6-48F5-BF1E-765FC47687D9 Q38872374-A07800EF-CA21-438C-9379-5D032DA7C057 Q38991205-45F99C8B-C48E-470F-8B38-DFED916F0EB7 Q39665401-ADBEA2E7-F35A-4E51-AA21-B85E714454F2 Q39771519-BEE3F856-309D-4EF3-A967-F17ECF553B9C Q40139991-F22ADD5D-930B-4D14-9252-19997A37C2CB Q40617761-7F1FFF5A-F2BE-40B9-85D2-BD9986A6AE73 Q41075817-5DF44A9C-238E-4F1A-A2F0-0BE7B01D6588 Q41876999-567A8CC8-B79E-4CC1-9A6E-215563281516 Q42216597-3B4BF024-E3E4-4E04-9562-1B9F950B711F Q42264085-F8EE3187-DBCA-456F-9ECC-B2DB11E4A639 Q42744998-8BCE5D78-1267-4809-9E2D-EA68A26AAFC2 Q44989494-482B1F2E-821B-48DA-94C9-914EA8826ADE Q46497112-D6A5294C-A1E8-4764-AEA3-60E589485E5B Q48156023-06270667-BF42-498E-B238-D0E890BFB1EC Q50028072-5CFA7036-29D7-4C12-99B3-A19A6EB1C14D Q52875965-E4095A61-9A67-4C63-A197-1359F09ED7C1

P2860

Pharmacokinetics of ertapenem in healthy young volunteers.

http://www.wikidata.org/entity/Q34141850

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Pharmacokinetics of ertapenem in healthy young volunteers.

@ast

Pharmacokinetics of ertapenem in healthy young volunteers.

@en

Pharmacokinetics of ertapenem in healthy young volunteers.

@nl

type

label

Pharmacokinetics of ertapenem in healthy young volunteers.

@ast

Pharmacokinetics of ertapenem in healthy young volunteers.

@en

Pharmacokinetics of ertapenem in healthy young volunteers.

@nl

prefLabel

Pharmacokinetics of ertapenem in healthy young volunteers.

@ast

Pharmacokinetics of ertapenem in healthy young volunteers.

@en

Pharmacokinetics of ertapenem in healthy young volunteers.

@nl

P1433

Q34141850-B8D7043D-4906-41A4-8D9D-2AA8C379579F

P1476

Q34141850-5F62DF21-38D1-4EA3-8321-D624896DB2B8

P2093

Q34141850-0F99C541-8BFF-4780-9E9C-0CA08C3B6682

Q34141850-15A3BD46-A84C-4B2F-B2BC-A5285D00B951

Q34141850-1C4CFFB5-A99B-45FC-815B-B325582C3410

Q34141850-1FDBD972-04BA-4517-8333-46735D201D15

Q34141850-2CF80BA8-D910-4156-B6D8-56DA72D351B6

Q34141850-51A6662A-1C97-4004-9C71-0BBACC5495C5

Q34141850-56CA30E3-37DD-462F-A927-D6A2B9A0CB57

Q34141850-672DE5DF-B28F-4EC8-AA1A-DCD03933D2AC

Q34141850-71A5B571-AFBB-4B97-851B-53B0F0938874

Q34141850-A57B2F56-C4EF-4E23-88AB-9AA61F548D2A

P2860

Q34141850-4EDEA7B8-5975-40EE-9441-DC3A7F46B87A

Q34141850-54328E13-E7F3-4B35-8F32-4E5FCA9F5D08

Q34141850-5D739BD3-D465-49C8-B677-EEACCE5DCE73

Q34141850-CF25A13D-4777-4400-AD05-987E3CCA2E06

Q34141850-F3E3692E-FEE5-4BD5-B839-51DE8512E3CD

P304

Q34141850-96F91367-4439-480B-B70D-7DD6CA8B8490

P31

Q34141850-5FDCEF4E-C8E7-4274-9739-D55C2F605B5E

P356

Q34141850-15D2F382-B507-4011-9827-C00E4A6097D0

P407

Q34141850-76041201-D08A-4114-A3AA-DE6B12753C7A

P433

Q34141850-4D757403-449B-42D0-90B6-63747EE23D2D

P478

Q34141850-31026691-16E4-48BF-8BDD-7131EFD67488

P50

Q34141850-63F34CF1-3C37-420F-BDE2-BA81B9BB9C50

P577

Q34141850-EC8405AA-B16F-4401-B52E-AAE2F1A03996

P698

Q34141850-1E041D62-0BE7-4B98-BA48-29DFCAD57B42

P932

Q34141850-89D78418-5DB6-44F2-BD08-BA676F457A3E

P356

AAC.46.11.3506-3511.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of ertapenem in healthy young volunteers

@en

P2093

A K Majumdar

http://www.w3.org/2001/XMLSchema#string

C J Kitchen

http://www.w3.org/2001/XMLSchema#string

D G Musson

http://www.w3.org/2001/XMLSchema#string

G Mistry

http://www.w3.org/2001/XMLSchema#string

H Greenberg

http://www.w3.org/2001/XMLSchema#string

J D Rogers

http://www.w3.org/2001/XMLSchema#string

J McCrea

http://www.w3.org/2001/XMLSchema#string

K L Birk

http://www.w3.org/2001/XMLSchema#string

L Xi

http://www.w3.org/2001/XMLSchema#string

M Hesney

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.

Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Plasma protein binding of ceftriaxone.

P304

3506-3511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.11.3506-3511.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Scott A. Waldman

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12384357

http://www.w3.org/2001/XMLSchema#string

P932

128708

http://www.w3.org/2001/XMLSchema#string